Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19

Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19

Rédigé le 11/04/2020
SOFMER


MD: Cas rapportés d un homme de 69 ans atteint de Covid-19 diagnostiqué en janvier 2020 à Wuhan, ainsi que deux autres patients avec forme grave de Covid-19 pec dans la même unité de soins intensifs. Une coagulopathie et des anticorps antiphospholipides ont été observés chez les trois patients.


We describe a patient with Covid-19 and clinically significant coagulopathy, antiphospholipid anti- bodies, and multiple infarcts. He was one of three patients with these findings in an intensive care unit designated for patients with Covid-19. This unit, which was managed by a multidisciplinary team from Peking Union Medical College Hospi- tal in the Sino–French New City Branch of Tongji Hospital in Wuhan, China, was set up on an emergency basis to accept the most critically ill patients during the outbreak of Covid-19. Severe acute respiratory syndrome coronavirus 2 (SARS-

CoV-2) infection was confirmed in all the patients by reverse-transcriptase–polymerase-chain-reaction (RT-PCR) assay or serologic testing.


nejmc2007575_coagulopathie_et_covid.pdf nejmc2007575_coagulopathie_et_covid